A naturally occurring amino acid, widely available as a dietary supplement, may offer a novel strategy for preventing the brain damage associated with Alzheimer’s disease. Researchers in Japan have discovered that arginine can significantly reduce the buildup of toxic amyloid proteins—the hallmark of Alzheimer’s—in both fruit fly and mouse models.
Unlike current treatments that attempt to remove existing plaque after it has formed, arginine appears to work by stopping the proteins from misfolding and clumping together in the first place. This preventive approach, combined with arginine’s established safety profile and low cost, positions it as a promising candidate for “drug repositioning”—repurposing existing compounds for new therapeutic uses.
The Challenge of Current Alzheimer’s Treatments
Alzheimer’s disease affects over 50 million people globally, a number projected to rise sharply with aging populations. The disease is characterized by the accumulation of amyloid beta (Aβ) proteins, which misfold and form sticky plaques that damage neurons and trigger chronic inflammation.
Recent advancements have introduced antibody drugs like lecanemab and donanemab, designed to clear these amyloid plaques from the brain. However, these treatments face significant hurdles:
* Modest Efficacy: Benefits for many patients remain limited.
* High Cost: Treatments can cost tens of thousands of dollars annually.
* Serious Side Effects: Risks include brain swelling and bleeding, known as amyloid-related imaging abnormalities (ARIA).
These limitations have spurred researchers to look for alternative mechanisms. Instead of clearing plaque post-formation, scientists are investigating ways to prevent the initial aggregation of amyloid proteins.
How Arginine Protects the Brain
Arginine is a common amino acid involved in essential bodily functions such as blood flow regulation, immune signaling, and wound healing. It belongs to a class of molecules known as chemical chaperones, which help proteins maintain their proper shape.
The study, led by Kanako Fujii and Professor Yoshitaka Nagai at Kindai University in Osaka, builds on previous findings where arginine reduced harmful protein aggregation in spinocerebellar ataxia type 6 (SCA6). The team hypothesized that this same mechanism could apply to Alzheimer’s disease.
In laboratory experiments, researchers observed that arginine directly inhibited the formation of Aβ42 fibrils, one of the most aggressive forms of amyloid beta. Higher concentrations of arginine resulted in stronger anti-aggregation effects. Electron microscopy revealed that amyloid fibers exposed to arginine were significantly shorter and less developed than those in untreated samples.
Evidence from Animal Models
The research team tested these findings in two distinct animal models to assess real-world biological impact.
1. Fruit Fly Models
Using genetically engineered fruit flies carrying the “Arctic” mutation linked to inherited Alzheimer’s, the researchers found that arginine reduced amyloid buildup and lessened neurotoxicity. This was measured by observing damage in the flies’ eyes, a standard indicator of protein toxicity in Drosophila studies. The protective effects were dose-dependent, meaning higher doses yielded better results.
2. Mouse Models
The study then utilized AppNL-G-F knock-in mice, which carry three human familial Alzheimer’s mutations and gradually develop amyloid plaques. Mice receiving arginine in their drinking water from an early age showed:
* Fewer Plaques: Significant reduction in amyloid plaques in the hippocampus and cortex, brain regions critical for memory.
* Targeted Mechanism: Arginine did not simply lower overall amyloid production. Instead, it specifically reduced levels of insoluble Aβ42 (the form that forms plaques) while leaving soluble amyloid levels largely unchanged. This confirms that arginine interferes with the aggregation process itself.
Behavioral and Inflammatory Benefits
Beyond structural changes in the brain, the mice treated with arginine showed functional improvements. In maze-based behavioral tests, these animals exhibited greater movement and exploratory activity compared to untreated Alzheimer’s model mice.
Furthermore, the treatment reduced the activity of inflammatory genes associated with cytokines such as IL-1β, IL-6, and TNF. These molecules are heavily linked to the chronic brain inflammation that drives Alzheimer’s progression.
“Our study demonstrates that arginine can suppress Aβ aggregation both in vitro and in vivo,” said Professor Nagai. “What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive, making it a highly promising candidate for repositioning as a therapeutic option for AD.”
Why This Matters: The Case for Drug Repositioning
The development of new Alzheimer’s drugs is notoriously difficult, often taking more than a decade and costing billions of dollars. Drug repositioning offers a faster, more cost-effective alternative by leveraging compounds with known safety profiles.
Because amyloid buildup can begin 15 to 20 years before memory symptoms appear, arginine’s potential as an oral, long-term preventive strategy is particularly appealing. It could be explored for individuals at elevated genetic risk, potentially intervening before irreversible damage occurs.
Important Caveats and Future Steps
Despite the promising results, researchers emphasize that this work remains at the preclinical stage. Animal models cannot fully replicate the complexity of human Alzheimer’s disease. The mice used in the study, for instance, do not develop all hallmarks of the condition, such as extensive neuron loss or tau tangles.
Additionally, the dosing used in the experiments does not match the amounts found in commercially available supplements. Therefore, consumers should not interpret these findings as an immediate recommendation to start taking arginine supplements for Alzheimer’s prevention.
“Our findings open up new possibilities for developing arginine-based strategies for neurodegenerative diseases caused by protein misfolding and aggregation,” Nagai noted. “Given its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer’s and potentially other related disorders.”
Larger preclinical studies and human clinical trials are required to determine if arginine can meaningfully slow disease progression in patients. If successful, this could shift the paradigm of Alzheimer’s treatment from reactive clearance to proactive prevention.
Reference:
“Oral administration of arginine suppresses Aβ pathology in animal models of Alzheimer’s disease” by Kanako Fujii et al., Neurochemistry International, 30 October 2025. DOI: 10.1016/j.neuint.2025.106082
